Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of this study is to validate the use of a rapid, at home, point-of-care (POC) SARS-CoV-2 IgG antibody test in high risk healthcare workers. Additionally, we would like to evaluate the incidence of seroconversion in this high-risk population and to identify possible candidates for convalescent plasma donation for therapy/prophylaxis.
Description: To validate the use of a rapid, at home, point-of-care (POC) SARS-CoV-2 IgG antibody test in high risk healthcare workers
Measure: Validation of SARS-CoV-2 IgG Antibody Test Time: April 2020-January 2021Description: To evaluate the incidence of seroconversion in this high-risk population
Measure: Incidence of Seroconversion Time: April 2020-January 2021Description: To identify possible candidates for convalescent plasma donation for therapy/prophylaxis (https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds)
Measure: Identify Candidacy Time: April 2020-January 2021